Trexquant Investment LP Zentalis Pharmaceuticals, Inc. Transaction History

Trexquant Investment LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$10.83 - $16.49 $409,698 - $623,816	37,830 New	37,830 $596,000
Q3 2023 Nov 13, 2023	SELL	$19.63 - $28.29 $312,941 - $450,999	-15,942 Reduced 39.4%	24,516 $491,000
Q2 2023 Aug 11, 2023	BUY	$17.41 - $30.05 $302,429 - $521,998	17,371 Added 75.24%	40,458 $1.14 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $372,624 - $575,789	23,087 New	23,087 $397,000
Q2 2022 Aug 11, 2022	BUY	$17.91 - $52.25 $23,694 - $69,126	1,323 Added 22.14%	7,298 $205,000
Q1 2022 May 13, 2022	SELL	$41.58 - $80.89 $377,795 - $734,966	-9,086 Reduced 60.33%	5,975 $276,000
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $1.01 Million - $1.28 Million	15,061 New	15,061 $1.27 Million
Q3 2021 Nov 12, 2021	SELL	$46.83 - $73.5 $279,528 - $438,721	-5,969 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$37.41 - $62.25 $223,300 - $371,570	5,969 New	5,969 $318,000
Q1 2021 May 13, 2021	SELL	$35.69 - $52.72 $242,620 - $358,390	-6,798 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$31.71 - $57.97 $215,564 - $394,080	6,798 New	6,798 $353,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $170M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.